A Single Ascending Dose Study for the Evaluation of the Effects of LY3039478 on the QT/Corrected QT Interval in Healthy Subjects and Pilot Relative Bioavailability
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2016
At a glance
- Drugs Crenigacestat (Primary)
- Indications Acute lymphoblastic leukaemia; Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 11 Jul 2016 Status changed from recruiting to completed.
- 14 Jun 2016 New formulation of LY3039478 added in the trial; number of treatment arms increased from 2 to 4.
- 07 Jun 2016 Planned number of patients changed from 15 to 29.